These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 29534592

  • 21. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
    Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.
    Blood; 2014 Apr 10; 123(15):2416-9. PubMed ID: 24553179
    [Abstract] [Full Text] [Related]

  • 22. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
    Broséus J, Park JH, Carillo S, Hermouet S, Girodon F.
    Blood; 2014 Dec 18; 124(26):3964-6. PubMed ID: 25305205
    [Abstract] [Full Text] [Related]

  • 23. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.
    Br J Haematol; 2016 Jul 18; 174(2):218-26. PubMed ID: 27061303
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
    Park SH, Kim SY, Lee SM, Yi J, Kim IS, Kim HH, Chang CL, Lee EY, Song MK, Shin HJ, Chung JS.
    Ann Lab Med; 2015 Mar 18; 35(2):233-7. PubMed ID: 25729726
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A.
    Leukemia; 2014 Jul 18; 28(7):1472-7. PubMed ID: 24402162
    [Abstract] [Full Text] [Related]

  • 28. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT, Quyen DT, Hoan NX, Giang DP, Trang TTH, Velavan TP, Bang MH, Song LH.
    BMC Med Genet; 2019 Jun 27; 20(1):115. PubMed ID: 31248375
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, Li S, Wang H, Liu W, Ma X, Guan M.
    J Hematol Oncol; 2014 Jul 15; 7():48. PubMed ID: 25023898
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.
    Basim Najm M, Jalal SD, Getta HA.
    Cell Mol Biol (Noisy-le-grand); 2022 Aug 31; 68(8):202-209. PubMed ID: 36800830
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.
    N Engl J Med; 2013 Dec 19; 369(25):2391-2405. PubMed ID: 24325359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.